1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Advanced Endometrial Carcinoma: new trials by email Literature Review of Advanced Endometrial Carcinoma trials Research Report on Advanced Endometrial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms (1) · Neoplasms by Site (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
Bevacizumab (1) · Carboplatin (1) · Disulfides (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Specimen Handling (1) · Taxes (1) · pembrolizumab (1)
National Cancer Institute (NCI) (1)
United States (1)
Amanda N Fader (1)
U10CA180868 (1)